This is particularly powerful in women with PCOS, perimenopausal weight gain, or metabolic sluggishnesswhere balancing hormones and blood sugar is key
The potentiation of endogenous SDF-1 by DPP-4 inhibitors could negate the benefits on atherosclerotic ischemic events that might be expected from enhanced GLP-1 signaling [59, 60] (Fig
Further studies are needed to investigate this hypothesis, but we suspect recent changes in medication prescribing practices and medication prices will result in large datasets allowing scientists to investigate these potential relationships. Christine Rode Schwarz, PhD, of the Steno Diabetes Center in Copenhagen, and her co-authors pointed to this case in a commentary titled, Mechanism and Context: Making Sense of Adverse Events With GLP-1-based Therapy , also published in JCEM Case Reports later that year
Eat fewer processed and sugary meals
The Medicinal-Chemistry Disclosure (2021) The primary design paper describing cagrilintide was published by Andreassen and colleagues in the Journal of Medicinal Chemistry in 2021 [1]
V.SouzaG